Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Posted on March 1st, 2019 by Nicki CatchpolePharma R&D
For many, many years, the findings of scientific research were published in an always-growing collection of scientific journals that spun off into more and more specialized disciplines. Today’s scientists have to think far beyond scholarly journals subscriptions and wrestle instead with search strategies and informatics.
Posted on March 1st, 2019 by Jabe WilsonPharma R&D
On February 28, events around the world are held in honor of Rare Disease Day, an annual occasion designed to raise awareness among the general public as well as among policy makers, government bodies, healthcare professionals and researchers. Rare diseases have become a major focus for cross-industry collaborations in recent years, and for good reason: (more…)
Posted on February 27th, 2019 by Nicki CatchpolePharma R&D
In December 2018, the FDA announced it has formally recognized a public database containing genomic information, a huge milestone in the evolving field of precision medicine. Now researchers can use this information to validate their tests instead of having to generate their own data.(more…)
Posted on February 26th, 2019 by Marnix WiefferPharma R&D
Adverse drug reactions can be costly and cost is just the tip of the iceberg. This is highlighted by an FDA website which cites troubling statistics such as the 100k deaths and over 2 million serious adverse drug reactions experienced each year…(more…)
Posted on February 25th, 2019 by Veaceslav MamaligaPharma R&D
As highlighted in my colleague, Nicki Catchpole’s last post on accidental drug discovery, 90 Years of Penicillin, the landscape of R&D is littered with ‘failures’ that turned out to be vital innovations. Pharmaceutical R&D is no exception.(more…)
Posted on January 26th, 2019 by adminPharma R&D
The process of discovering a viable drug candidate molecule is often time-consuming and research-intensive. A lab must test thousands of compounds every day — and a hit rate of just 1 percent is considered above average.
About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, its affiliates and sponsors or its parent company, Reed Elsevier.